Drug Profile
Research programme: influenza vaccines - GenVec
Alternative Names: Influenza vaccines - GenVec/NIAIDLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator GenVec
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Influenza-virus-infections in USA (Parenteral)
- 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
- 04 Sep 2013 Research programme: influenza vaccines - GenVec is available for licensing as of 04 Sep 2013. http://www.genvec.com